At a recent conference, Jazz Pharmaceuticals presented positive efficacy results from the JZP-110 (TONES) studies in adult patients with sleep impairment conditions and the excessive sleepiness associated with these diseases. This excessive sleepiness is a severe symptom of the rare condition, narcolepsy, and brings on many other associated problems, including impairments in function, concentration, social interactions, and overall quality of life. For more information about narcolepsy, click here.
The TONES 2 JZP-110 study in particular focused on narcolepsy, and it found that patients who had been administered doses of JZP-110 had significant improvements in two measures of wakefulness: the Maintenance of Wakefulness Test and the Epworth Sleepiness Scale.
In addition to these measures, patients also self-reported an increased ability to stay awake and a decreased subjective level of sleepiness.
These changes were sustained over the full course of the study, and further, were consistent with the findings of the previous Phase 2 studies of JZP-110.
JZP-110 works because it is a dopamine and norepinephrine reuptake inhibitor that blocks the actions of both of these neurotransmitters. Thus, it is an innovative treatment option that focuses on the underlying neurological cause of excessive sleepiness.
Chief medical officer of Jazz Pharmaceuticals, Karen Smith relayed that the company is
“committ[ed] to making significant research and development investments to find innovative treatments for unmet medical needs in sleep medicine.”
Subsequent studies have completed enrollment, the results of which are suspected to support the anticipated JZP-110 New Drug Application (NDA) submission to the U.S. FDA by the end of this year, so it may not be long before narcolepsy patients get the relief that they need!
In the meantime, if you want to learn more about JZP-110, click here.
